Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pLM-fSV2A Citations (3)

Originally described in: Genomic safe harbors permit high I
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M Nat Biotechnol. 2010 Dec 12. ():.
PubMed Journal

Articles Citing pLM-fSV2A

Articles
KLF4 N-terminal variance modulates induced reprogramming to pluripotency. Kim SI, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K. Stem Cell Reports. 2015 Apr 14;4(4):727-43. doi: 10.1016/j.stemcr.2015.02.004. Epub 2015 Mar 12. PubMed

Associated Plasmids

Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Kang R, Zhou Y, Tan S, Zhou G, Aagaard L, Xie L, Bunger C, Bolund L, Luo Y. Stem Cell Res Ther. 2015 Aug 18;6:144. doi: 10.1186/s13287-015-0137-7. PubMed
PTBP1 acts as a dominant repressor of the aberrant tissue-specific splicing of ISCU in hereditary myopathy with lactic acidosis. Rawcliffe DFR, Osterman L, Nordin A, Holmberg M. Mol Genet Genomic Med. 2018 Nov;6(6):887-897. doi: 10.1002/mgg3.413. Epub 2018 Sep 12. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.